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Background: Outcome data in “real-world” patients on dual antiplatelet treatment with prasugrel and aspirin is limited. Data from SCAAR (Swedish 
Coronary and Angiography and Angioplasty Registry) on patient characteristics and in-hospital bleeding rates in acute coronary syndrome (ACS) 
patients with prasugrel or clopidogrel treatment were analyzed.
Methods: Consecutive patients with ACS undergoing invasive treatment in the SCAAR database between 01 May 2010 and 01 April 2011 were 
included in this study. Patients were treated with either prasugrel 10 mg once daily (o.d) (with initial prasugrel loading dose (LD) 60 mg or 
clopidogrel LD 300-600 mg) or clopidogrel 75 mg o.d (with initial clopidogrel LD 300-600 mg), both co-administred with aspirin 75 mg o.d. All 
treatment interventions were performed according to current standards and were at discretion of the treating physician. The outcome was SCAAR 
defined bleeding during the initial hospitalization. Data are presented as percentages and compared with a Chi-square test.
Results: In total 1077 prasugrel and 8441 clopidogrel treated patients with ACS underwent PCI. Prasugrel treated patients were younger, more 
often male, had a greater body weight (P for all <0.05), and tended to have less risk factors or a less extensive previous medical history. Of prasugrel 
treated patients 214 (20%) were above 75 years old and 41 (3.8%) below 60 kg body weight. A clopidogrel LD was administered in 65.4% of the 
prasugrel-treated patients before invasive treatment. Prasugrel use was more frequent in ST-segment elevation myocardial infarction (STEMI) than 
in non-ST segment elevation myocardial infarction (NSTEMI) and unstable angina (UA) (prasugrel: 58% and 42%; clopidogrel: 32% and 68%, for 
STEMI and NSTEMI/UA respectively). Any SCAAR-reported minor or major bleeding during the index hospitalization bleeding occurred in 0.5% of the 
prasugrel and 3.3% of the clopidogrel patients (p<0.01).
Conclusion: During this first year, “real-world” experience of prasugrel in Sweden shows that prasugrel was predominately prescribed in younger 
patients with STEMI. In this patient group, prasugrel as compared to clopidogrel was not associated with an increased bleeding rate.
